Prostate high dose rate brachytherapy in a free-standing cancer center setting

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 5, 2007, Pages 520-525

  Tharp, Morgan ^a,c   Bennett, Richard ^b   Burns, Jennifer ^b   Jones, W Terry ^b   Scheidler, David ^b   Serbin, Philip ^b   Stuhldreher, David ^b   Vaught, Jeff ^b   Wang, Yun ^a  

^a Central Indiana Cancer Centers   (United States)

^b Urology of Indiana   (United States)

^c Central Indiana Cancer Centers   (United States)

Author keywords

Brachytherapy; Conformal radiotherapy; Interstitial radiotherapy; Prostate cancer; Targeted radiotherapy

Indexed keywords

GONADORELIN AGONIST;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; DISEASE DURATION; DISEASE SEVERITY; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT SAFETY; PATIENT TRANSPORT; PHYSICIAN; PROSTATE CARCINOMA; RADIATION DOSE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; URINE CATHETER;

BRACHYTHERAPY; DYSURIA; HUMANS; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SAFETY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 35148830423     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31804b45a9     Document Type: Article

References (20)

1. Stromberg J, Martinez A, Gonzalez J, et al. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 1995;33:161-171.
2. Demanes DJ, Rodriquez RR, Altieri GA. High dose rate prostate brachytherapy: the California Endocurietherapy (CET) Method. Radiother Oncol. 2000;57:289-296.
3. Galalae RM, Kovacs G, Schultze J, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2002;52:81-90.
4. Mate TP, Gottesman JE, Hatton J, et al. High dose-rate afterloading 192-Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys. 1998;41:525-533.
5. Borghede G, Hedelin H, Holmang S, et al. Combined treatment with temporary short-term high dose rate Iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol. 1997;44:237-244.
6. Dinges S, Deger S, Koswig S, et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer: results of a prospective trial. Radiother Oncol. 1998;48:197-202.
7. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:316-327.
8. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306-1316.
9. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia: the Measurement Committee of the American Urological Association. J Urol. 1992;148:1549-1557.
10. Partin AW, Yoo J, Carter HB, et al. The use of prostatic specific antigen, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
11. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243-1252.
12. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280-1283.
13. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
14. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-106.
15. Deger S, Boehmer D, Turk I, et al. High dose rate brachytherapy of localized prostate cancer. Eur Urol. 2002;41:420-426.
16. Martinez A, Gonzalez J, Spencer W, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169:974-980.
17. Valicenti RK, Winter K, Cox JD, et al. RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys. 2003;57:614-620.
18. Martin T, Roddiger S, Kurek R, et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol. 2004;71:35-41.
19. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098-1104.
20. Pellizzon ACA, Nadalin W, Salvajoli JV, et al. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer. Radiother Oncol. 2003;66:167-172.